Effect of an experimental medication on thinking and memory in schizophrenia
Part of Mental health clinical trials.
This study tests a new combination medication (xanomeline/trospium) to see if it helps improve thinking and memory problems in people with schizophrenia. It lasts about a year, and participants continue their usual antipsychotic treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be between 18 and 55 years old
- Have a diagnosis of schizophrenia (confirmed by a doctor)
- Currently on a stable dose of an oral antipsychotic medication for at least 4 weeks
- Have some cognitive (thinking) difficulties, as measured by a short test
- Not be pregnant, breastfeeding, or at high risk for suicide
- Not have certain health conditions (like significant kidney, liver, or bladder problems)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new combination medication (xanomeline/trospium) for people with early schizophrenia who want to switch antipsychotics. The goal is to see if it helps control symptoms and is easier to tolerate.
This study tests two ways of switching from your current antipsychotic to a new combination medication (xanomeline and trospium). The goal is to see which approach is safer and easier for people with schizophrenia.
This study tracks how satisfied people with schizophrenia are with a new combination medicine called xanomeline and trospium chloride (XT). It aims to understand real-world experiences and benefits of this treatment.
This trial tests whether a new oral medication, KarXT, can help prevent a return of schizophrenia symptoms in people who have been stable on treatment. If you've had a hospital stay in the past year and still have some symptoms, you may be able to join.
This study tests a new treatment that may help with thinking and memory problems in people with schizophrenia. It is for people whose schizophrenia symptoms are stable and who are already on a steady medication.
This trial tests an investigational drug, KYN-5356, to see if it can improve thinking and memory problems in adults with schizophrenia. You may join if your schizophrenia is stable and you take only one antipsychotic medication.
Hear when a new Schizophrenia; Psychosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.